A Phase 2 interventional study of Modafinil and Placebo in Crohn Disease (CD), Ulcerative Colitis (UC) and Fatigue, sponsored by Imperial College London. Recruiting at 4 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Imperial College London · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 217 studies in Crohn Disease with a site in United Kingdom — 47 open to participants now, 66 under way, 26 of them phase 3. Crohn Disease · United Kingdom.
Among the 217 studies in Crohn Disease with a site in United Kingdom, this one is the 122nd largest by planned enrollment of the 171 interventional ones that give a count, is one of 9 that started in 2026, is one of 44 in phase 2, reaches primary completion later than 33 of the 65 other live ones, and was the 207th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →47 of the 217 studies in Crohn Disease with a site in United Kingdom are open now. Recruiting first, the newest first:
Agomab Spain S.L.U. · Sites in United Kingdom, United States, Serbia
Ages 18+
Agomab Spain S.L.U. · Sites in United Kingdom
Ages 30–65 · Men only · Healthy volunteers
Hoffmann-La Roche · Sites in United Kingdom, United States, Australia and 5 more countries
Ages 2–17
Takeda · Sites in United Kingdom
Ages 18–75
University of Nottingham · Sites in United Kingdom
Ages 16+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
217 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 49 · Phase 3 75 · Phase 4 9
First in 2000; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 168 across the 171 interventional studies, 245 across the 46 observational. Of the 135 that completed or were terminated, 75 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
137 of 217 have an industry lead sponsor. The 10 most frequent:
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Imperial College London has 2 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Crohn Disease with a site in United Kingdom that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
Add all 15 to your calendar (.ics) → With an account.
Among the 217 studies in Crohn Disease with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Fatigue is a big problem in people with inflammatory bowel disease (IBD). Even when IBD is well controlled, 50% of patients remain fatigued most of the time. Fatigue can be physical (e.g. feeling tired or weak) and mental (e.g. brain fog). However, there are no effective treatments for IBD fatigue.
Modafinil is a medication that can rapidly improve fatigue. It usually acts within 30 minutes and improves wakefulness. It can also improve brain fog. Modafinil has been used for over 30 years in people with narcolepsy, which is a condition where people fall asleep during the day. Modafinil has also been used in people who do not have narcolepsy.
This study will compare modafinil with a dummy tablet (placebo) in people with IBD. This is a feasibility study. This means it primarily aims to test whether a trial like this can be conducted in people with IBD.
Half of the patients in the study will receive modafinil and half will receive placebo. Treatment will be 12 weeks. Patients will start by taking 1 tablet and will then increase to 2 tablets and then 3 tablets if needed. A computer will randomly allocate treatment, meaning there is an equal chance of being allocated modafinil or placebo. They will be followed up after 6 weeks and 12 weeks.
Being a feasibility study, the investigators will measure how many patients consent to the study; how many complete treatment; and how acceptable the treatment is. Participants will complete a range of questionnaires measuring fatigue, mental health and gut health, primarily to look at the completeness and spread of data, and to obtain estimates of treatment effects and their variance.
If feasible, this study will support a larger version of the trial.
Design: The current study is a randomised controlled trial (a study in which people are allocated by chance to receive different interventions). The trial will compare mirtazapine against a placebo (dummy) tablet in 70 patients with both severe fatigue and IBD. This is a feasibility study, meaning that it is testing whether it will be possible to do a larger version of this study.
Setting: Consent and assessments will take placebo in clinic rooms or clinical research facilities at Imperial College Healthcare National Health Service (NHS) Foundation Trust, King's College Hospital, St Mark's Hospital and Guy's and St Thomas' Hospital, or online if the patient prefers this. The latter is important in maximising participation to the study for participants who may find it difficult to access hospitals, which is a common problem in inflammatory bowel disease (IBD) due to issues like pain and incontinence.
Recruitment: Consecutive patients aged ≥18 with diagnosed IBD and significant fatigue will be identified from outpatient clinics and biologics infusion suites. If possible, clinicians will use the IBD Fatigue Scale to identify people scoring ≥11. If necessary, patients will be identified from screening of endoscopy schedules and IBD multidisciplinary team meetings. The clinical team will seek the patient's permission to be contacted by the research team.
If they agree, the research team will then contact the patient - either in the clinic or over the phone - and provide the patient information sheet. The research team will check some basic pre-screening questions: confirming IBD diagnosis, duration of fatigue, whether they are planned to change any IBD treatments in the next 12 weeks, and the 5- question IBD Fatigue Assessment Scale if not already completed. Before pre-screening, the research team will advise patients that the fatigue information they provide will be passed onto their clinical team - with their permission - even if they decide not to take part in the study. They will be advised that any other information about their IBD will not be retained by the study team if they do not wish to take part. If anyone has an elevated fatigue score but does not wish to take part in the study, the research team will seek the patient's permission to relay the fatigue score to their clinical team.
Those who are deemed to be potentially eligible after pre-screening will be invited for a full screening assessment with a member of the study team. Final study inclusion and consent will be taken by a study doctor.
Study procedures: There will be 4 main study visits. At the first visit, the researcher will explain the study in detail. They will answer any questions the participant has. They will ask the participant some brief questions about their mental health and gut health. They will complete the IBD Fatigue Scale if not already done to ensure they score ≥11/20. The research team will confirm that their fatigue is at least 6 months in duration. If eligible according to screening criteria, the research team will invite them to participate and to sign a consent form.
The researchers will check that the participant meets all the inclusion criteria and none of the exclusion criteria. They will ask the participant more detailed questions about fatigue and mental health (the National Institute for Health and Care Excellent (NICE) criteria for chronic fatigue syndrome, Mini Neuropsychiatric Interview for depression) and will complete further questionnaires lasting around 20 minutes. They will also be asked to have height and weight measured and to provide a blood sample (though these are not compulsory). They will have their hand grip strength tested. If female and of childbearing age, the researcher will take a blood pregnancy test. If they are eligible to take part, the participant will then be randomised by computer to one of the 2 treatments (modafinil or placebo). The tablets for both groups are made to look the same. Neither participant nor the research team will know in which treatment group they are allocated to.
Participants will be given medication the same day or will receive it via recorded post.
The 2 treatment arms are:
The participant will meet with the research team again at 6 and 12 weeks after starting treatment. This can be in person or online. These appointments will last for around 30 minutes and will involve:
Although they will finish treatment after 12 weeks, the investigators will participants whether they can attend a final visit 6 weeks later. This is not compulsory. It will involve repeating most of the questionnaires. Throughout, participants will still be able to access any talking therapies for depression or fatigue, though should not start any other antidepressants.
Progression criteria: The milestones for progression to a full efficacy clinical trial will be based on the proportion-to-target of patients randomised overall; % completing 12 weeks of treatment; % of participants taking at least 75% of prescribed mediation; % of planned data and samples collected at 12 weeks; and % participants describing the treatment as acceptable (≥6/10 on 0-10 scale).
Sample size: As a feasibility study, power calculations for a treatment effect are not applicable. The investigators will recruit 70 participants (35 per group), which is sufficient to generate robust variance estimates. Based on 70 patients and an anticipated follow-up rate of 80%, a two-sided confidence interval will extend no more than 12% of the observed proportion.
Data management:
Data will be collected on paper case report form (CRF) and then transferred to an electronic case report form (eCRF). The type of activity that an individual user may undertake is regulated by the privileges associated with his/her user identification code and password. All forms and tapes related to study data will be kept in locked cabinets. Access to the study data will be restricted. The database will be password-protected.
Statistical methods:
A statistical analysis plan (SAP) will be approved by the Trial Steering Committee independent statistician. The analysis population will use intention-to-treat principles. A recruitment plot of predicted vs. actual recruitment will be generated on a monthly basis.
Participant flow through the study will be presented. Descriptive data will be presented in the form of means and standard deviations; medians and ranges; or percentages with 95% confidence intervals, as appropriate depending on the data being described. The investigators will use linear mixed models to estimate the between group adjusted mean difference (aMD) between mirtazapine and placebo groups at week 12 after adjustment for baseline scores, time, and a treatment-by-time-interaction. Associated 95% confidence intervals will be presented alongside the aMD without p-values. More details will be provided in the statistical analysis plan.
Timeline: This 24-month study includes up to 5 months for setup and approval, 12 months for recruitment (plus 3 months' contingency), 4 months for follow-up visits (including post-treatment follow-ups) and 3 months for write-up and dissemination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 capsule, increasing if needed after 2 weeks to 2 capsules, increasing if needed after 2 weeks to 3 capsules. Total treatment duration 12 weeks.
Drug: Placebo
1 x 100mg, increasing if needed after 2 weeks to 2 x 100mg, increasing if needed after 2 weeks to 3 x 100mg. Total treatment duration 12 weeks.
Drug: Modafinil
100-300mg daily according to patient response
1-3 placebo capsules according to patient response
Recruitment rate
Participants randomised overall, percentage of target
Time frame: 2 years
Trial adherence
Percentage of participants completing 12 weeks of treatment
Time frame: 12 weeks
Treatment adherence
Percentage of participants taking at least 75% of prescribed mediation
Time frame: 12 weeks
Study procedures acceptability and compliance
Percentage of planned data and samples collected at primary endpoint (12 weeks)
Time frame: 12 weeks
Overall acceptability
Percentage of participants describing the treatment as acceptable (≥6/10 on 0-10 scale)
Time frame: 12 weeks
First 5 questions of the Inflammatory Bowel Disease-Fatigue questionnaire
Range 0-20, higher scores indicate worse fatigue
Time frame: 12 weeks
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale
Range 0-52, higher scores indicate less fatigue
Time frame: 12 weeks
Patient Health Questionnaire-9
Range 0-27, higher scores indicate worse depression
Time frame: 12 weeks
Generalised Anxiety Disorder-7
Range 0-21, higher scores indicate worse anxiety
Time frame: 12 weeks
Maudsley 3-item Visual Analogue Scale
Range 0-300, higher scores indicate worse depression
Time frame: 12 weeks
Pittsburgh Sleep Quality Index
Range 0-21, higher scores indicate worse sleep
Time frame: 12 weeks
Euroqol 5-dimension quality of life questionnaire (EQ-5D-5L)
Range 0-1, higher scores indicate better quality of life
Time frame: 12 weeks
Harvey Bradshaw Index (Crohn's disease patients only)
Higher scores indicate worse disease activity
Time frame: 12 weeks
Simple Clinical Colitis Activity Index (ulcerative colitis patients only)
Higher scores indicate worse disease activity
Time frame: 12 weeks
Inflammatory Bowel Disease Control Questionnaire
Range 0-16, higher scores indicate better disease activity
Time frame: 12 weeks
Hand grip strength
Range 0-100kg, higher scores indicate better hand grip strength
Time frame: 12 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started May 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.
Of 84 phase 2 interventional studies under Crohn Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's planned 18 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → May 2026, on Nov 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Modafinil